NCT07637474Recruiting
Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 18 Feb 2025
- Start date
- Jul 2024
- Primary completion date
- Jul 2026
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Lung cancer
- NCT number
- NCT07637474
What you commit to
- Study type: Observational
- Planned participants: 150
- From Jul 2024 to the primary completion date, Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to immunotherapy
- Contraindication to immunotherapy
- Locally advanced disease candidate for concomitant chemo-radiotherapy treatment
- For the third cohort
- previously treated patients
Other
- Unavailability of tumor tissue
- Histotype with neuroendocrine or mixed component
- For the second cohort
- Histotype with neuroendocrine or mixed component
Who the study is looking for
- Age \> 18 years
- Histological diagnosis of advanced stage NSCLC
- Histotype adenocarcinoma and squamous carcinoma
- ECOG PS \<2
- Known PDL-1 stage
- Measurable disease
- Availability of tumor tissue
- No evidence of molecular drivers
- Written informed consent (to the study and data processing)
- For the second cohort in addition to the precedents it is included
- Diagnosis of limited or locally advanced NSCLC deemed resectable
- For the third cohort in addition to the precedents it is included
- patients candidates for surgery for non-small cell lung cancer
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS National Cancer institute Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.